Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead

Gilles Nevez, Solène Le Gal
Gilles Nevez
aGroupe d’Étude des Interactions Hôte-Pathogène (GEIHP)-EA 3142, Université de Brest, Brest, France
bLaboratoire de Mycologie et Parasitologie, CHRU de Brest, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Solène Le Gal
aGroupe d’Étude des Interactions Hôte-Pathogène (GEIHP)-EA 3142, Université de Brest, Brest, France
bLaboratoire de Mycologie et Parasitologie, CHRU de Brest, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01296-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • TABLE 1

    Main reports on Pneumocystis pneumonia treatment using caspofungin

    Author(s) (reference), yr of publicationPatient status (no. of patients)bRegimenaTreatment efficacy or failure
    Beltz et al. (5), 2006ALL (1)CAS and SMX-TMPEfficacy
    Zhang et al. (6), 2006COPD (1)CAS and SMX-TMPEfficacy
    Annaloro et al. (7), 2006BMTR (1)CAS and SMX-TMPEfficacy
    Utili et al. (8), 2007RTR (4)CAS and SMX-TMPEfficacy
    Mu et al. (9), 2009CML (1)CAS and SMX-TMPEfficacy
    Ceballos et al. (10), 2011HIV infection (1)CAS and SMX-TMPEfficacy
    Armstrong-James et al. (11), 2011HIV infection (4)CAS and SMX-TMPEfficacy
    Tu et al. (12), 2013RTR (3)CAS and SMX-TMPEfficacy
    Lee et al. (13), 2016HIV (1)CAS and SMX-TMPEfficacy
    Lu et al. (14), 2017HTR (1)CAS and SMX-TMPEfficacy
    Zhang et al. (15), 2018Non-HIV immunosuppression (14)CAS and SMX-TMPEfficacy
    Koshi et al. (16), 2019Sjogren’s syndrome (1)CAS and SMX-TMPEfficacy
    Hof and Schnülle (18), 2008Wegener’s disease (1)CASEfficacy
    Lee et al. (19), 2017HIV infection (1)CAScEfficacy
    Huang et al. (20), 2018Autoimmune diseases (2)CAScEfficacy
    Huang et al. (21), 2019HIV infection (7)CAScEfficacy/failured
    Kamboj et al. (22), 2006Cancer (2)CASFailure
    Kim et al. (23), 2013HIV-infection (4)CASFailure
    • ↵a CAS and SMX-TMP, caspofungin and sulfamethoxazole-trimethoprim combination; CAS, caspofungin.

    • ↵b ALL, Acute lymphoblastic leukemia; COPD, chronic obstructive pulmonary disease; RTR renal transplant recipient; CML, chronic myelomonocytic leukemia; HIV, human immunodeficiency virus; HRT, heart transplant recipient; BMTR, bone marrow transplant recipient.

    • ↵c CAS as second-line treatment.

    • ↵d Efficacy, 4 out of 7 cases.

PreviousNext
Back to top
Download PDF
Citation Tools
Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
Gilles Nevez, Solène Le Gal
Antimicrobial Agents and Chemotherapy Sep 2019, 63 (10) e01296-19; DOI: 10.1128/AAC.01296-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
Gilles Nevez, Solène Le Gal
Antimicrobial Agents and Chemotherapy Sep 2019, 63 (10) e01296-19; DOI: 10.1128/AAC.01296-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

caspofungin
echinocandin
Pneumocystis jirovecii

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596